{"id":692151,"date":"2022-10-04T16:33:15","date_gmt":"2022-10-04T20:33:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\/"},"modified":"2022-10-04T16:33:15","modified_gmt":"2022-10-04T20:33:15","slug":"p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\/","title":{"rendered":"P3 Health Partners Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal"},"content":{"rendered":"

<\/p>\n

P3 Health Partners Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal<\/i><\/b><\/p>\n

Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company\u2019s Securities<\/b><\/i><\/p>\n

The Company Intends to Submit All Periodic Reports and Hold an Earnings Call the Week of October 17, 2022<\/b><\/i><\/p>\n

HENDERSON, Nev.–(BUSINESS WIRE<\/a>)–
\nP3 Health Partners Inc. (\u201cP3\u201d or the \u201cCompany\u201d) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that on September 28, 2022 it received a Staff Delisting Determination (the \u201cStaff Determination\u201d) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) notifying the Company that Nasdaq has initiated a process which could result in the delisting of the Company\u2019s securities from Nasdaq as a result of the Company not being in compliance with Nasdaq Listing Rule 5250(c)(1) (the \u201cListing Rule\u201d), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the \u201cSEC\u201d). The Staff Determination has no immediate effect and will not immediately result in the suspension of trading or delisting of the Company\u2019s securities.\n<\/p>\n

\nThe Company intends to appeal the Staff Determination before a Nasdaq Hearing Panel and seek a further stay of any suspension or delisting action pending the hearing process in accordance with the procedures set forth in the Staff Determination Letter. The Company is working diligently with its current and former auditors to complete the previously disclosed restatement and the audit of the financial statements for the fiscal year ended December 31, 2021. The Company currently believes it will submit all delinquent periodic reports to the SEC before or during the week of October 17, 2022, which will bring the Company back into compliance with the Listing Rule.\n<\/p>\n

\nThe Staff Determination was issued because the Company has not filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the \u201cForm 10-K\u201d) or its Quarterly Reports on Form 10-Q for the quarterly period ended March 31, 2022 (the \u201cFirst Quarter Form 10-Q\u201d) and June 30, 2022 (the \u201cSecond Quarter Form 10-Q\u201d) by the Extension Deadline (defined below).\n<\/p>\n

\nAs previously disclosed, Nasdaq had granted the Company a period of 180 calendar days from the prescribed due date of the Form 10-K, or until September 27, 2022 (the \u201cExtension Deadline\u201d), to file the Form 10-K, First Quarter Form 10-Q, and Second Quarter Form 10-Q to regain compliance with the Listing Rule. The Company previously disclosed the delay in and circumstances behind the late filing of each of the Form 10-K, the First Quarter Form 10-Q and Second Quarter Form 10-Q in a Notification of Late Filing on Form 12b-25, filed with the SEC on March 31, 2022, May 17, 2022, and August 16, 2022, respectively.\n<\/p>\n

\nThe Company\u2019s request for a hearing before the Nasdaq Hearing Panel to appeal the Staff Determination must be made no later than 4:00 p.m. Eastern Time on October 5, 2022. The hearing request will automatically stay the suspension of the Company\u2019s securities for a period of 15 days from the date of the request. In connection with its request for a hearing, the Company also intends to request that the Staff Determination be further stayed pending the hearing process. According to the Staff Determination, hearings are typically scheduled to occur approximately 30-45 days after the date of a company\u2019s hearing request. Following the hearing, the Hearings Panel will issue a decision, which the Company may further appeal to the Nasdaq Listing Council for review. The Company is working diligently to file the delinquent periodic reports as soon as possible to regain compliance with the Listing Rule. However, there can be no assurance that such periodic reports will be filed before any hearing occurs or that the Nasdaq Hearing Panel will grant the Company\u2019s request for a stay pending the hearing process.\n<\/p>\n

About P3 Health Partners (NASDAQ: PIII):<\/b><\/p>\n

P3 Health Partners Inc.<\/a> is a leading population health management company committed to transforming healthcare by improving the lives of both patients and providers. Founded and led by physicians, P3 has an expansive network of more than 2,500 affiliated primary care providers across the country. Our local teams of health care professionals manage the care of thousands of patients in 18 counties across five states. P3 supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, the P3 care team creates an enhanced patient experience by navigating, coordinating, and integrating the patient\u2019s care within the healthcare system. For more information, visit www.p3hp.org<\/a> and follow us on @p3healthpartners<\/a> and Facebook.com\/p3healthpartners<\/a>.\n<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. Words such as “anticipate,” “believe,” “budget,” “contemplate,” “continue,” “could,” “envision,” “estimate,” “expect,” “guidance,” “indicate,” “intend,” “may,” “might,” “plan,” “possibly,” “potential,” “predict,” “probably,” “pro-forma,” “project,” “seek,” “should,” “target,” or “will,” or the negative or other variations thereof, and similar words or phrases or comparable terminology, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the Company\u2019s appeal to the Nasdaq Hearings Panel and request for a stay of the Nasdaq delisting process and the timing of the filing of the Company\u2019s delinquent periodic reports and the timing of the earnings call, which reflect the Company\u2019s expectations based upon currently available information and data.\n<\/p>\n

\nBecause such statements are based on the Company\u2019s current expectations and are not statements of fact, actual results may differ materially from those projected or estimated and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements, including, but not limited to, the risk that the completion and filing of the 2021 Form 10-K, First Quarter Form 10-Q and the Second Quarter Form 10-Q take longer than expected, the risk that Nasdaq does not grant the Company\u2019s request for a stay pending the hearing process or does not grant the Company\u2019s request for continued listing and other factors discussed in the \u201cRisk Factors\u201d section of the Company\u2019s Registration Statement on Form S-1 filed with the SEC on December 28, 2021 and in the Company\u2019s other filings with the SEC. All information in this press release is as of the date hereof. The Company disclaims and does not undertake any obligation to update or revise any forward-looking statement in this report, except as required by applicable law or regulation.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20221004006078\/en\/<\/a><\/span><\/p>\n

Communications
\n<\/b>
Kassi Belz
\n
Executive Vice President, Communications
\n
P3 Health Partners
\n
(904) 415-2744
\n
kbelz@p3hp.org<\/a><\/p>\n

Investor Relations
\n<\/b>
Karen Blomquist
\n
Vice President, Investor Relations
\n
P3 Health Partners
\n
kblomquist@p3hp.org<\/a><\/p>\n

\nSteve Halper
\n
Managing Director
\n
LifeSci Advisors
\n
shalper@lifesciadvisors.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Nevada<\/p>\n

INDUSTRY KEYWORDS:<\/b> Health Consumer Hospitals Practice Management Seniors Managed Care General Health<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

P3 Health Partners Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company\u2019s Securities The Company Intends to Submit All Periodic Reports and Hold an Earnings Call the Week of October 17, 2022 HENDERSON, Nev.–(BUSINESS WIRE)– P3 Health Partners Inc. (\u201cP3\u201d or the \u201cCompany\u201d) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that on September 28, 2022 it received a Staff Delisting Determination (the \u201cStaff Determination\u201d) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) notifying the Company that Nasdaq has initiated a process which could result in the delisting of the Company\u2019s securities from Nasdaq as … <\/p>\n

Continue reading “P3 Health Partners Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-692151","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nP3 Health Partners Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"P3 Health Partners Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"P3 Health Partners Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company\u2019s Securities The Company Intends to Submit All Periodic Reports and Hold an Earnings Call the Week of October 17, 2022 HENDERSON, Nev.–(BUSINESS WIRE)– P3 Health Partners Inc. (\u201cP3\u201d or the \u201cCompany\u201d) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that on September 28, 2022 it received a Staff Delisting Determination (the \u201cStaff Determination\u201d) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) notifying the Company that Nasdaq has initiated a process which could result in the delisting of the Company\u2019s securities from Nasdaq as … Continue reading "P3 Health Partners Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-04T20:33:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221004006078r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"P3 Health Partners Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal\",\"datePublished\":\"2022-10-04T20:33:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\\\/\"},\"wordCount\":1219,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20221004006078r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\\\/\",\"name\":\"P3 Health Partners Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20221004006078r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2022-10-04T20:33:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20221004006078r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20221004006078r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"P3 Health Partners Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"P3 Health Partners Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\/","og_locale":"en_US","og_type":"article","og_title":"P3 Health Partners Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal - Market Newsdesk","og_description":"P3 Health Partners Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company\u2019s Securities The Company Intends to Submit All Periodic Reports and Hold an Earnings Call the Week of October 17, 2022 HENDERSON, Nev.–(BUSINESS WIRE)– P3 Health Partners Inc. (\u201cP3\u201d or the \u201cCompany\u201d) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that on September 28, 2022 it received a Staff Delisting Determination (the \u201cStaff Determination\u201d) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) notifying the Company that Nasdaq has initiated a process which could result in the delisting of the Company\u2019s securities from Nasdaq as … Continue reading \"P3 Health Partners Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-04T20:33:15+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221004006078r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"P3 Health Partners Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal","datePublished":"2022-10-04T20:33:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\/"},"wordCount":1219,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221004006078r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\/","name":"P3 Health Partners Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221004006078r1&sid=flmnd&distro=nx&lang=en","datePublished":"2022-10-04T20:33:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221004006078r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221004006078r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"P3 Health Partners Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692151","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=692151"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692151\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=692151"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=692151"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=692151"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}